TELA Bio Files 8-K on Financials
Ticker: TELA · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
TL;DR
TELA Bio dropped an 8-K on March 20th covering financials and operations.
AI Summary
On March 20, 2025, TELA Bio, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing also included disclosures related to Regulation FD and financial statements. The company is incorporated in Delaware and headquartered in Malvern, Pennsylvania.
Why It Matters
This 8-K filing provides investors with crucial updates on TELA Bio's financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial information and does not indicate any unusual or immediate risks.
Key Players & Entities
- TELA Bio, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Malvern, Pennsylvania (location) — Principal executive offices
- March 20, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for TELA Bio, Inc.?
The primary purpose is to report on TELA Bio, Inc.'s Results of Operations and Financial Condition, as well as provide Regulation FD Disclosures and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 20, 2025.
Where is TELA Bio, Inc. headquartered?
TELA Bio, Inc.'s principal executive offices are located at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355.
What is TELA Bio, Inc.'s state of incorporation?
TELA Bio, Inc. is incorporated in Delaware.
What is the SEC file number for TELA Bio, Inc.?
The SEC file number for TELA Bio, Inc. is 001-39130.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 regarding TELA Bio, Inc. (TELA).